Benitec Biopharma to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference

Reuters02-23

<a href="https://laohu8.com/S/BNTC">Benitec Biopharma</a> to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference

Benitec Biopharma Inc. will present a late-breaking poster (No. 501 LB) with interim results from its BB-301 Phase 1b/2a treatment study in oculopharyngeal muscular dystrophy at the Muscular Dystrophy Association Clinical & Scientific Conference in Orlando, Florida on March 9, 2026. Event link: https://www.globenewswire.com/Tracker?data=pLLeaDqKLCgrfh2JJSt8g6N61VtPQabhTN3pc3SJHp5yBdPw5YR-tnrRkP5yJzrQ8mIVRgLq74uJxwYJOfuPXukZnlqsB6oGBNghMJajblNkw8cUbmqiVWYbTNZpu-2buGk_c_z_6C9_VuaejMMWXkkKHBbUREUiWdyxSB7ekYQ=

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602230700PRIMZONEFULLFEED9658871) on February 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613781816?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-23 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613781816","market":"nz","top_or_hot":-1,"title":"Benitec Biopharma to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BNTC\">Benitec Biopharma</a> to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BLT.AU\">Benitec Biopharma</a> Inc. will present a late-breaking poster (No. 501 LB) with interim results from its BB-301 Phase 1b/2a treatment study in oculopharyngeal muscular dystrophy at the Muscular Dystrophy Association Clinical &amp; Scientific Conference in Orlando, Florida on March 9, 2026. Event link: https://www.globenewswire.com/Tracker?data=pLLeaDqKLCgrfh2JJSt8g6N61VtPQabhTN3pc3SJHp5yBdPw5YR-tnrRkP5yJzrQ8mIVRgLq74uJxwYJOfuPXukZnlqsB6oGBNghMJajblNkw8cUbmqiVWYbTNZpu-2buGk_c_z_6C9_VuaejMMWXkkKHBbUREUiWdyxSB7ekYQ=\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602230700PRIMZONEFULLFEED9658871) on February 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Benitec Biopharma to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBenitec Biopharma to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-23 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BNTC\">Benitec Biopharma</a> to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BLT.AU\">Benitec Biopharma</a> Inc. will present a late-breaking poster (No. 501 LB) with interim results from its BB-301 Phase 1b/2a treatment study in oculopharyngeal muscular dystrophy at the Muscular Dystrophy Association Clinical &amp; Scientific Conference in Orlando, Florida on March 9, 2026. Event link: https://www.globenewswire.com/Tracker?data=pLLeaDqKLCgrfh2JJSt8g6N61VtPQabhTN3pc3SJHp5yBdPw5YR-tnrRkP5yJzrQ8mIVRgLq74uJxwYJOfuPXukZnlqsB6oGBNghMJajblNkw8cUbmqiVWYbTNZpu-2buGk_c_z_6C9_VuaejMMWXkkKHBbUREUiWdyxSB7ekYQ=\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602230700PRIMZONEFULLFEED9658871) on February 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDLbV5d7q:1","article_id":"2613781816","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613781816","pubTimestamp":1771848111,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Benitec Biopharma to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BNTC":"Benitec Biopharma Limited","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Benitec Biopharma将在肌营养不良协会临床和科学会议上展示BB-301 1b/2a期中期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTC":0.9,"NDAQ":0.9},"content_text":"Benitec Biopharma to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference\n    \n\nBenitec Biopharma Inc. will present a late-breaking poster (No. 501 LB) with interim results from its BB-301 Phase 1b/2a treatment study in oculopharyngeal muscular dystrophy at the Muscular Dystrophy Association Clinical & Scientific Conference in Orlando, Florida on March 9, 2026. Event link: https://www.globenewswire.com/Tracker?data=pLLeaDqKLCgrfh2JJSt8g6N61VtPQabhTN3pc3SJHp5yBdPw5YR-tnrRkP5yJzrQ8mIVRgLq74uJxwYJOfuPXukZnlqsB6oGBNghMJajblNkw8cUbmqiVWYbTNZpu-2buGk_c_z_6C9_VuaejMMWXkkKHBbUREUiWdyxSB7ekYQ=\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602230700PRIMZONEFULLFEED9658871) on February 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613781816","isCrawlerRequest":true}